300 related articles for article (PubMed ID: 15738295)
1. Bosentan therapy for portopulmonary hypertension.
Hoeper MM; Halank M; Marx C; Hoeffken G; Seyfarth HJ; Schauer J; Niedermeyer J; Winkler J
Eur Respir J; 2005 Mar; 25(3):502-8. PubMed ID: 15738295
[TBL] [Abstract][Full Text] [Related]
2. Combination therapy for portopulmonary hypertension with intravenous iloprost and oral bosentan.
Halank M; Kolditz M; Miehlke S; Schiemanck S; Schmeisser A; Hoeffken G
Wien Med Wochenschr; 2005 Aug; 155(15-16):376-80. PubMed ID: 16160926
[TBL] [Abstract][Full Text] [Related]
3. Use of a mixed endothelin receptor antagonist in portopulmonary hypertension: a safe and effective therapy?
Kuntzen C; Gülberg V; Gerbes AL
Gastroenterology; 2005 Jan; 128(1):164-8. PubMed ID: 15633133
[TBL] [Abstract][Full Text] [Related]
4. Efficiency and safety of bosentan in child C cirrhosis with portopulmonary hypertension and renal insufficiency.
Barth F; Gerber PJ; Reichen J; Dufour JF; Nicod LP
Eur J Gastroenterol Hepatol; 2006 Oct; 18(10):1117-9. PubMed ID: 16957519
[TBL] [Abstract][Full Text] [Related]
5. Bosentan treatment of portopulmonary hypertension related to liver cirrhosis owing to hepatitis C.
Grander W; Eller P; Fuschelberger R; Tilg H
Eur J Clin Invest; 2006 Sep; 36 Suppl 3():67-70. PubMed ID: 16919014
[TBL] [Abstract][Full Text] [Related]
6. Experience with inhaled iloprost and bosentan in portopulmonary hypertension.
Hoeper MM; Seyfarth HJ; Hoeffken G; Wirtz H; Spiekerkoetter E; Pletz MW; Welte T; Halank M
Eur Respir J; 2007 Dec; 30(6):1096-102. PubMed ID: 17652314
[TBL] [Abstract][Full Text] [Related]
7. Successful treatment of portopulmonary hypertension with bosentan: case report.
Stähler G; von Hunnius P
Eur J Clin Invest; 2006 Sep; 36 Suppl 3():62-6. PubMed ID: 16919013
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of bosentan treatment for portopulmonary hypertension associated with syncope.
Sato A; Maie K; Ohno Y; Yoshida T; Ito E; Tanabe Y; Aizawa Y
Int Heart J; 2011; 52(4):243-5. PubMed ID: 21828952
[TBL] [Abstract][Full Text] [Related]
9. Bosentan therapy for pulmonary arterial hypertension.
Rubin LJ; Badesch DB; Barst RJ; Galie N; Black CM; Keogh A; Pulido T; Frost A; Roux S; Leconte I; Landzberg M; Simonneau G
N Engl J Med; 2002 Mar; 346(12):896-903. PubMed ID: 11907289
[TBL] [Abstract][Full Text] [Related]
10. Endothelin-receptor antagonist treatment of portopulmonary hypertension.
Hinterhuber L; Graziadei IW; Kähler CM; Jaschke W; Vogel W
Clin Gastroenterol Hepatol; 2004 Nov; 2(11):1039-42. PubMed ID: 15551258
[TBL] [Abstract][Full Text] [Related]
11. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial.
Jaïs X; D'Armini AM; Jansa P; Torbicki A; Delcroix M; Ghofrani HA; Hoeper MM; Lang IM; Mayer E; Pepke-Zaba J; Perchenet L; Morganti A; Simonneau G; Rubin LJ;
J Am Coll Cardiol; 2008 Dec; 52(25):2127-34. PubMed ID: 19095129
[TBL] [Abstract][Full Text] [Related]
12. Long-term safety, tolerability and efficacy of bosentan in adults with pulmonary arterial hypertension associated with congenital heart disease.
Diller GP; Dimopoulos K; Kaya MG; Harries C; Uebing A; Li W; Koltsida E; Gibbs JS; Gatzoulis MA
Heart; 2007 Aug; 93(8):974-6. PubMed ID: 17639112
[TBL] [Abstract][Full Text] [Related]
13. Treatment with a combination of bosentan and sildenafil allows for successful liver transplantation in a patient with portopulmonary hypertension.
Sağ S; Yeşilbursa D; Güllülü S
Turk J Gastroenterol; 2014 Aug; 25(4):429-32. PubMed ID: 25254528
[TBL] [Abstract][Full Text] [Related]
14. Bosentan for the treatment of adult pulmonary hypertension.
Dwyer N; Kilpatrick D
Future Cardiol; 2011 Jan; 7(1):19-37. PubMed ID: 21174507
[TBL] [Abstract][Full Text] [Related]
15. Successful switch from inhalative iloprost to oral bosentan in portopulmonary hypertension associated with liver cirrhosis.
Molnar C; Alber H; Colleselli D; Vogel W; Kähler CM
Wien Klin Wochenschr; 2004 Sep; 116(17-18):627-30. PubMed ID: 15515882
[TBL] [Abstract][Full Text] [Related]
16. Effect of the oral endothelin antagonist bosentan on the clinical, exercise, and haemodynamic status of patients with pulmonary arterial hypertension related to congenital heart disease.
Apostolopoulou SC; Manginas A; Cokkinos DV; Rammos S
Heart; 2005 Nov; 91(11):1447-52. PubMed ID: 15761050
[TBL] [Abstract][Full Text] [Related]
17. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study.
Channick RN; Simonneau G; Sitbon O; Robbins IM; Frost A; Tapson VF; Badesch DB; Roux S; Rainisio M; Bodin F; Rubin LJ
Lancet; 2001 Oct; 358(9288):1119-23. PubMed ID: 11597664
[TBL] [Abstract][Full Text] [Related]
18. Efficacy, safety and pharmacokinetics of bosentan in portopulmonary hypertension.
Savale L; Magnier R; Le Pavec J; Jaïs X; Montani D; O'Callaghan DS; Humbert M; Dingemanse J; Simonneau G; Sitbon O
Eur Respir J; 2013 Jan; 41(1):96-103. PubMed ID: 22653773
[TBL] [Abstract][Full Text] [Related]
19. Bosentan for the treatment of pulmonary arterial hypertension associated with congenital heart defects.
Sitbon O; Beghetti M; Petit J; Iserin L; Humbert M; Gressin V; Simonneau G
Eur J Clin Invest; 2006 Sep; 36 Suppl 3():25-31. PubMed ID: 16919007
[TBL] [Abstract][Full Text] [Related]
20. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions.
Denton CP; Humbert M; Rubin L; Black CM
Ann Rheum Dis; 2006 Oct; 65(10):1336-40. PubMed ID: 16793845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]